Jan 10, 2023 / 05:45PM GMT
Anupam Rama - JPMorgan Chase & Co, Research Division - VP and Analyst
Welcome, everyone, to the Tuesday morning of the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Malcolm Kuno and Priyanka Grover from the team. Our next presenting company is Ultragenyx. And presenting on behalf of the company, we have the CEO, Emil Kakkis. Emil?
Emil D. Kakkis - Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director
Thank you, Anupam. Happy to be here today in person. Hustle and bustle of JPMorgan again. It's great. So we're happy to be back in the mode and I want to give you an update on Ultragenyx. Where we are today. This is our forward-looking statement.
Our mission since 2010, I think it's been going beyond every day to change the lives of rare disease patients. And we've been successful in doing that with 4 approved products and 5 indications in that time frame, treating more than 3,000 patients globally.
And we've done it with precision
Ultragenyx Pharmaceutical Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers